Drug resistance is of great concern in cancer treatment because most effective drugs are
limited by the development of resistance following some periods of therapeutic …

Acute Myeloid Leukaemia (AML) is a commonly occurring severe haematological
malignancy, with most patients exhibiting sub-optimal clinical outcomes. Therapy resistance …

Abstract Purpose: Cyclin-dependent kinase 9 (CDK9) is a transcriptional regulator and
potential therapeutic target for many cancers. Multiple nonselective CDK9 inhibitors have …

The bone marrow (BM) is the primary site of adult haematopoiesis, where stromal elements
(eg fibroblasts and mesenchymal stem cells [MSCs]) work in concert to support blood cell …

Objectives Venetoclax combined with hypomethylating agents is a new therapeutic strategy
frequently used for treating AML patients who are not eligible for conventional …

Abstract The replicative Cdc45-MCM-GINS (CMG) helicase is a large protein complex that
functions in the DNA melting and unwinding steps as a component of replisomes during …

The curative potential of allogeneic hematopoietic cell transplantation (allo-HCT) in the
treatment of acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) …

Specific inhibition of CDK9 is considered a promising strategy for developing effective
anticancer therapeutics. However, most of the reported CDK9 inhibitors are still at an early …

Bone marrow microenvironment (BMM) is the main sanctuary of leukemic stem cells (LSCs)
and protects these cells against conventional therapies. However, it may open up an …

The prognosis for many patients with acute myeloid leukemia (AML) is poor, mainly due to
disease relapse driven by leukemia stem cells (LSCs). Recent studies have highlighted the …